Patents by Inventor Paul Mortenson

Paul Mortenson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240043428
    Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
    Type: Application
    Filed: December 21, 2022
    Publication date: February 8, 2024
    Inventors: Gilbert BESONG, Christopher Thomas BRAIN, Clinton A. BROOKS, Miles Stuart CONGREVE, Claudio DAGOSTIN, Guo HE, Ying HOU, Steven HOWARD, Yue LI, Yipin LU, Paul MORTENSON, Troy SMITH, Moo Je SUNG, Steven WOODHEAD, Wojciech WRONA, Bharat LAGU
  • Publication number: 20210253578
    Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
    Type: Application
    Filed: September 16, 2020
    Publication date: August 19, 2021
    Inventors: Gilbert BESONG, Christopher Thomas BRAIN, Clinton A. BROOKS, Miles Stuart CONGREVE, Claudio DAGOSTIN, Guo HE, Ying HOU, Steven HOWARD, Yue LI, Yipin LU, Paul MORTENSON, Troy SMITH, Moo Je SUNG, Steven WOODHEAD, Wojciech WRONA, Bharat LAGU
  • Publication number: 20180155351
    Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
    Type: Application
    Filed: February 1, 2018
    Publication date: June 7, 2018
    Inventors: Gilbert Besong, Christopher Thomas Brain, Clinton A. Brooks, Miles Stuart Congreve, Claudio Dagostin, Guo He, Ying Hou, Steven Howard, Yue Li, Yipin Lu, Paul Mortenson, Troy Smith, Moo Je Sung, Steven Woodhead, Wojciech Wrona, Bharat Lagu
  • Publication number: 20170183352
    Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
    Type: Application
    Filed: August 8, 2016
    Publication date: June 29, 2017
    Applicants: Novartis AG, Astex Therapeutics Ltd.
    Inventors: Gilbert BESONG, Christopher Thomas BRAIN, Clinton A. BROOKS, Miles Stuart CONGREVE, Claudio DAGOSTIN, Guo HE, Ying HOU, Steven HOWARD, Yue LI, Yipin LU, Paul MORTENSON, Troy SMITH, Moo Je SUNG, Steven WOODHEAD, Wojciech WRONA, Bharat LAGU
  • Patent number: 9416136
    Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: August 16, 2016
    Assignees: Novartis AG, Astex Therapeutics, Ltd.
    Inventors: Gilbert Besong, Christopher Thomas Brain, Clinton A Brooks, Miles Stuart Congreve, Claudio Dagostin, Guo He, Ying Hou, Steven Howard, Yue Li, Yipin Lu, Paul Mortenson, Troy Smith, Moo Je Sung, Steven Woodhead, Wojciech Wrona, Bharat Lagu
  • Publication number: 20150270679
    Abstract: Systems and methods for fabricating capacitive discharge electrodes for a ring laser gyroscope are disclosed. In one example, a laser block for generating a laser in a closed loop path comprises a laser block, wherein an optically closed loop path is formed within the laser block. Additionally, at least two electrodes are formed on the laser block, wherein the at least two electrodes are used in conjunction with a radio frequency power supply to create an electric potential in the laser block which generates at least one laser beam in the closed loop path. The at least two electrodes are manufactured by placing a paste composition on the laser block and securing the paste composition to the laser block. The paste composition also includes a conductive material.
    Type: Application
    Filed: March 21, 2014
    Publication date: September 24, 2015
    Applicant: Honeywell International Inc.
    Inventors: Rodney Harold Thorland, Douglas Paul Mortenson, Bruce A. Seiber
  • Publication number: 20110152232
    Abstract: Compounds that modulate GHS-R are described, for examples compounds formula (I)
    Type: Application
    Filed: October 26, 2010
    Publication date: June 23, 2011
    Inventors: Jeffrey O. Saunders, Thomas Coulter, Paul Mortenson, Manuel A. Navia, Jean-Francois Pons
  • Patent number: 7829589
    Abstract: Compounds that modulate GHS-R are described, for examples compounds formula (I)
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: November 9, 2010
    Assignee: Elixir Pharmaceuticals, Inc.
    Inventors: Jeffrey O. Saunders, Thomas Coulter, Paul Mortenson, Manuel A. Navia, Jean-Francois Pons
  • Publication number: 20100105653
    Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
    Type: Application
    Filed: August 21, 2009
    Publication date: April 29, 2010
    Inventors: Gilbert Besong, Christopher Thomas Brain, Clinton A. Brooks, Miles Stuart Congreve, Claudio Dagostin, Guo He, Ying Huo, Steven Howard, Yue Li, Yipin Lu, Paul Mortenson, Troy Smith, Moo Je Sung, Steven Woodhead, Wojciech Wrona
  • Publication number: 20070270473
    Abstract: Compounds that modulate GHS-R are described, for examples compounds formula (I)
    Type: Application
    Filed: November 29, 2006
    Publication date: November 22, 2007
    Inventors: Jeffrey Saunders, Thomas Coulter, Paul Mortenson, Manuel Navia, Jean-Francois Pons
  • Publication number: 20060293370
    Abstract: Compounds that modulate GHS-R are described, for examples compounds formula (I)
    Type: Application
    Filed: June 12, 2006
    Publication date: December 28, 2006
    Inventors: Jeffrey Saunders, Thomas Coulter, Paul Mortenson, Manuel Navia, Jean-Francois Pons